Quest Diagnostics (DGX) FY2025 10-K Annual Report
Quest Diagnostics (DGX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Quest Diagnostics FY2025 10-K Analysis
Business Overview
- • Largest national lab services provider: ~$11.0B net revenue in 2025, serving ~⅓ of U.S. adult population annually and processing 244 million test requisitions
- • Advanced Diagnostics™ five-franchise segment (oncology, cardiometabolic, brain health, autoimmune, women's health) surpassed $1B revenue on double-digit growth
- • Haystack Oncology MRD ctDNA test received FDA Breakthrough Device Designation in 2025 for early-stage colorectal cancer, with clinical trials launched at Mass General Brigham and Rutgers Cancer Institute
- • Project Nova launched Feb 2025: multi-year Epic-powered "Order to Cash" modernization targeting completion 2031–2032; Google Cloud generative AI collaboration also announced in 2025
- • LifeLabs acquisition (2024) added ~6,800 employees and ~23 million Canadian test requisitions in first full year, bringing global headcount to nearly 57,000
Management Discussion & Analysis
- • Revenue $11.0B in FY2025; no explicit YoY dollar comparison provided in the MD&A text
- • Advanced Diagnostics segment — oncology, cardiometabolic, brain health, autoimmune, women's health/genetics — exceeded $1B revenue on double-digit growth
- • Hospital channel: reference testing ~$1.2B; Collaborative Lab Solutions ~$800M in 2025
- • Capital return: quarterly dividend raised ~7.5% to $0.86/share; ~$8.1B returned via buybacks since 2012
- • Key risks: PAMA reimbursement reform pending, Project Nova IT modernization through 2031–2032, and evolving AI/regulatory landscape
Risk Factors
- • PAMA reimbursement reform risk: Congress introduced 2025 Results Act to fix structural flaws; prior 2018-2020 cuts exceeded original 10-year savings projections
- • Debt load $5.7B outstanding as of Dec 31, 2025 with restrictive covenants limiting operational flexibility
- • IT modernization via multi-year Project Nova, partnered with Epic; system failure could disrupt billing and customer service operations
- • AI-enabled point-of-care and home testing competitors threatening volume; hospitals internalizing advanced testing without commercial labs
- • Tariffs and trade policy uncertainty raising supply chain costs for testing equipment and materials across international operations
Quest Diagnostics FY2025 Key Financial MetricsXBRL
Revenue
$11.0B
▲ +11.8% YoY
Net Income
$992M
▲ +13.9% YoY
Operating Margin
14.1%
▲ +47bp YoY
Net Margin
9.0%
▲ +17bp YoY
ROE
13.8%
▲ +99bp YoY
Total Assets
$16.2B
▲ +0.4% YoY
EPS (Diluted)
$8.75
▲ +13.8% YoY
Operating Cash Flow
$1.9B
▲ +41.4% YoY
Source: XBRL data from Quest Diagnostics FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Quest Diagnostics
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.